

Proceedings

# Divers Transformations Leading to New Potent GPx Mimetics †

Jacek Ścianowski \*, Agata J. Pacuła-Miszewska, Magdalena Obieziurska-Fabisiak and Anna Laskowska

Department of Organic Chemistry, Faculty of Chemistry, Nicolaus Copernicus University, 7 Gagarin Street, 87-100 Torun, Poland; pacula@umk.pl (A.J.P.-M.); magdao@umk.pl (M.O.-F.); annlas@doktorant.umk.pl (A.L.)

\* Correspondence: jsch@umk.pl

† Presented at the 1st International Electronic Conference on Catalysis Sciences, 10–30 November 2020;

Available online: <https://eccs2020.sciforum.net>.

Published: 9 November 2020


**Abstract:** Designing a highly active and selective Se-therapeutic that mimics the activity of the antioxidant enzyme glutathione peroxidase (GPx) still remains a challenge. Since the discovery of ebselen (*N*-phenyl-1,2-benzisoselenazol-3(2H)-one) and its ability to act as a GPx mimetic, the search for more effective peroxide scavengers has become a “hot topic” in this field of research. Herein, we present several modifications of the benzoselenazolone core that enable improving the antioxidant and anticancer potential of the basic ebselen structure. These transformations include (a) the installation of chiral terpene skeletons, from *p*-menthane, pinane, and carane systems, on the nitrogen atom; (b) exchange of the carbonyl oxygen atom for sulfur to obtain thiocarbonyl derivatives; (c) oxidation of the selenium moiety resulting in a series of benzenoselenenic acids and their further transformation to corresponding water-soluble potassium salts; and (d) attachment of an additional phenyl group leading to variously *N*-substituted unsymmetrical phenylselenides with an *o*-amido function. All of the synthesized compounds were tested as antioxidants and antiproliferative agents. Conclusions concerning the structure–activity correlation, including the difference in the reactivity of specific Se-moieties (-Se-N-, -SeOOH, -SeOOK, -SePh), *N*-substituents (the influence of bulky aliphatic moiety and the three-dimensional orientation of atoms), and incorporated heteroatoms (-C=O, -C=S) are presented.

**Keywords:** ebselen; organoselenium derivatives; antioxidant activity; anticancer activity

## 1. Introduction

Reactive oxygen species (ROS) play an important role as mediators and regulators in the cells physiology [1,2]. However, their intense and long-lasting effect can have a destructive impact on biomolecules, such as DNA, lipids, or proteins and consequently cause a whole range of diseases, e.g., cardiovascular disorders, cancer, neurodegeneration, and aging [3–5]. Therefore, the production of ROS must be strictly controlled by the enzymatic and non-enzymatic antioxidant systems in order to avoid the disorder of homeostasis between pro- and antioxidant processes, which are defined as “oxidative stress” [6,7]. The selenoenzyme–glutathione peroxidase (GPx) is an important part of this bio-machinery. Ebselen (*N*-phenyl-1,2-benzisoselenazol-3(2H)-one) was one of the first organoselenium compounds to be discovered as a GPx mimic. Although ebselen was found to have very promising antioxidant properties, several side effects and low solubility prompted the search for specific structural modifications that could improve its bioavailability and reduce the observed negative after-effects. Until now, we have performed several transformations of the benzoselenazolone core that enable modifying the bio-activity of the basic ebselen structure. These

modifications included (a) exchanging the oxygen atom of a carbonyl group for a sulfur atom to form thiocarbonyl derivatives; (b) substitution of the nitrogen atom with chiral skeletons; (c) oxidation of the Se-N bond to form selenenic acids -SeOOH and its subsequent transformation into the water-soluble seleninic acid potassium salts; and (d) transformation of the Se-N bond into a selenide moiety (Scheme 1).



**Scheme 1.** Structural modification of *N*-substituted benzisoselenazol-3(2*H*)-ones.


The conducted transformations enabled obtaining a variety of Se-based GPx mimics. All derivatives were tested as antioxidants and anticancer agents. The influence of specific modifications on the activity of the molecules is highlighted.

## 2. Results and Discussion

### 2.1. Synthesis of Benzisoselenazol-3-(2*H*)-Thiones

The exchange of the carbonyl oxygen atom with a sulfur atom, in the structure of benzisoselenazol-3-(2*H*)-ones, reduces the polarity of the double bond. This can influence the stability of the Se-N bond and its reactivity toward ROS (antioxidant properties) and proteins (the rate of S-Se bond formation). Based on this assumption, we have developed an efficient methodology for the preparation of benzisoselenazol-3-(2*H*)-thions using Lawesson's reagent [8].

*N*-alkylbenzisoselenazolthiones **3a–f** were obtained by two different two-step methods. The first of them (Method A) involved the reaction of *N*-alkyl-*o*-iodobenzamides **1** with Lawesson's reagent (L.R.), which was followed by the nucleophilic substitution of the obtained thioamides by  $\text{Li}_2\text{Se}_2$ . The second procedure (Method B) was based on the formation of benzisoselenazol-3-(2*H*)-ones **4** in the reaction of *N*-alkyl-*o*-iodobenzamides **1** with  $\text{Li}_2\text{Se}_2$  [9] and then the reaction of ebselen derivatives **4** with Lawesson's reagent (Scheme 2).




**Scheme 2.** Methods A and B used to obtain thio-derivatives **3a–f**.

The reaction of amides **1** with Lawesson's reagent, carried out under standard conditions (**route a**) [10], allowed obtaining the thioamides **2** in only moderate yields (reaction time: 12 h, yields: 22–61%). Performing the same reaction using microwave radiation (**route b**), under solvent-free conditions, significantly shortened the reaction time (3 min) and improved the yields of the process (44–82%).

## 2.2. Synthesis of *N*-terpenyl Benzoselenazol-3(2*H*)-Ones

As chiral compounds that possess a strictly defined orientation of substituents on the asymmetric carbon can interact with specific biological targets differently, depending on their configuration and the structure of the matching receptor, we also wanted to synthesize a series of chiral *N*-substituted benzoselenazolones, including different enantiomers, epimers, and regioisomers, and determine the correlation between the structure of the compound and its biological activity.


For this purpose, we have first synthesized a series of terpene amines by a multistep methodology starting from the corresponding alcohol (*p*-menthane system) or alkene (pinene and carene systems), which were further converted to corresponding benzoselenazol-3(2*H*)-ones **7–14** by the reaction with 2-(chloroseleno)benzoyl chloride **6** (Scheme 3) [11].



**Scheme 3.** Synthesis of *N*-terpenyl benzoselenazol-3(2*H*)-ones **7–14**.

## 2.3. Synthesis of Seleninic Acid Potassium Salts

The main way to improve the bioavailability of a chemical compound is to increase its solubility in body fluids. The moderate antioxidant activity of ebselen is mainly related to its poor solubility in water, which becomes particularly important when attempting to administer the drug intravenously. To address this issue, we have conducted the synthesis of water-soluble derivatives in the form of potassium salts of 2-(*N*-alkylcarboxamido)benzeneseleninic acids **17a–f**. The first step of the research involved the synthesis of *N*-alkylbenzeneseleneneinic acids **16a–f** with *o*-amide function. The acids **16a–f** were obtained using two alternative methods: by oxidation of *N*-alkylbenzoselenazol-3(2*H*)-ones **4a–f** (Method C) or the corresponding diselenides **15a–f** (Method D) with 30%  $\text{H}_2\text{O}_2$ . *N*-alkylbenzeneselenenic acids **16a–f** in the next step were converted into the corresponding benzeneselenenic salts **17a–f** by reaction with potassium *tert*-butoxide in anhydrous ethanol (Scheme 4) [12].




**Scheme 4.** Synthesis of benzeneselenenic acids **16a–f** and corresponding potassium salts **17a–f**.

## 2.4. Synthesis of *N*-substituted Unsymmetrical Phenylselenenides

The simplicity of including aromatic or heteroaromatic rings in the structure of a compound and the possibility of their easy modification may turn out to be a way to increase the activity of the pharmacophore [13,14]. Taking this into account, we attempted to install an additional phenyl ring in the structure of ebselen and synthesize a series of *N*-substituted asymmetric phenylselenenides bearing an *o*-amide group **19b–35b**.

The first step of the research involved the synthesis of N-substituted o-iodobenzamides **19a–35a** by the reaction of amines with o-iodobenzoyl chloride **18**. The resulting benzamides **19a–35a** were converted into the corresponding N-aliphatic, N-aromatic, and chiral N-terpene phenylselenenides **19b–35b** using a newly developed procedure involving nucleophilic copper-catalyzed substitution by Se-nucleophile generated in situ from diphenyl diselenide and sodium borohydride (Scheme 5) [15].




**Scheme 5.** Synthesis of N-substituted phenylselenenides **19b–35b**.

### 2.5. Evaluation of the Antioxidant Activity

All obtained derivatives were tested as antioxidants using the popular NMR test developed by Iwaoka and co-workers [16]. The results with the highest antioxidant potential are presented in Table 1.

**Table 1.** Results of the antioxidant activity measurement.



Catalyst [0.1 equiv.]	Remaining Dithiotreitol (%)				
	3 min	5 min	15 min	30 min	60 min
<b>Benzisoselenazolthiones</b>					
<b>3b</b>	43	21	3	2	0
<b>3e</b>	40	26	18	17	15
<b>N-terpenyl benzisoselenazol-3(2H)-ones</b>					
<b>10/11</b>	71	39	5	0	0
<b>12</b>	74	61	28	6	0
<b>Benzeneseleninic acids</b>					
<b>16e</b>	76	56	38	24	12
<b>16f</b>	85	64	37	18	2
<b>Seleninic acid potassium salts</b>					
<b>17a–f</b>	0	0	0	0	0
<b>Phenylselenides</b>					
<b>21a</b>	57	39	16	4	0
<b>22a</b>	98	97	94	88	71
<b>Ebselen</b>	84	75	64	58	52

Due to the fact that the change of the -SOOH group to the -SOOK group resulted in a drastic increase in activity (the reaction was completed in 3 min), all benzeneselenenic acid salts **17a–f** were evaluated by the same procedure but using 0.01 equivalent of the Se catalyst (Table 2).

**Table 2.** Results of the antioxidant activity measurement for salts.

Catalyst [0.01 equiv.]	Remaining Dithiotreitol (%)				
	3 min	5 min	15 min	30 min	60 min
<b>Seleninic acid potassium salts</b>					
<b>17a</b>	24	11	0	0	0
<b>17e</b>	59	16	0	0	0
<b>Ebselen</b>	97	96	95	94	92

The most important features improving the antioxidant activity was the presence of a bulky substituent that probably enables the facile cleavage of the Se-N bond (*N*-terpene derivatives **10–12**) and good solubility in water (benzeneselenenic acid salts **17a–f**).

### 2.6. Evaluation of the Cytotoxic Activity

The cytotoxic activity of the obtained derivatives was evaluated by the cell viability assay (MTT) on breast cancer MCF-7 [17] and human promyelocytic leukemia HL-60 cell lines. The IC<sub>50</sub> values for compounds with the best results are presented in Table 3.

**Table 3.** Cytotoxic activity evaluated in vitro.

	MCF-7	HL-60		MCF-7	HL-60
	IC <sub>50</sub> , μM			IC <sub>50</sub> , μM	
<b><i>N</i>-terpenyl benzisosenazol-3(2H)-ones</b>			<b>Seleninic acid potassium salts</b>		
<b>10</b>	19.9 ± 0.4	7.1 ± 0.4	<b>17f</b>	16.6 ± 1.1	42.1 ± 3.1
<b>11</b>	13.3 ± 1.1	20.6 ± 1.0	<b>Phenylselenides</b>		
<b>7</b>	12.4 ± 0.4	12.4 ± 0.9	<b>31b</b>	16.35 ± 0.29	16.3 ± 0.16
<b>8</b>	85.5 ± 4.0	61.3 ± 3.2	<b>Carboplatin</b>		
<b>Benzeneselenenic acids</b>				0.70 ± 0.30	3.19 ± 0.46
<b>16a</b>	40.1 ± 1.2	11.7 ± 1.0			

In the case of benzisosenazolones and phenylselenides, the attachment of chiral bulky terpene substituents seemed to enhance the cytotoxic potential. Although the antiproliferative activity of all derivatives was lower than for the known drug carboplatin, the difference of reactivity of two enantiomeric pairs *N*-pinocampheyl **10** and **11** and *N*-menthyl derivatives **7** and **8** present an interesting example that the biological activity can be selectively modified by incorporating specific chiral structures on the nitrogen atom of the benzisosenazolone core.

### 3. Conclusions

Herein, we have presented various modifications of the benzisosenazolone core that enable improving the antioxidant and anticancer potential of the basic ebselen structure. The compounds with the highest antioxidant potential were the benzeneselenenic acid potassium salts **17a–f**. The best obtained antioxidant was 2-(*N*-ethylcarboxyamido)benzeneselenenic acid potassium salt **17a**, used in only 0.01 equivalent, for which the lack of substrate was observed after 15 min of reaction time. Among all tested derivatives, the highest antioxidant activity was observed for compounds with a 3-methylbutyl substituent. The highest antiproliferative potential toward the HL-60 cell line exhibited *N*-isopinocampheyl-1,2-benzisosenazol-3(2H)-one **10** (IC<sub>50</sub> of 7.1 ± 0.4 μM) and against MCF7 the *N*-menthyl-1,2-benzisosenazol-3(2H)-one **7** (IC<sub>50</sub> of 12.4 ± 0.4 μM).

## References

1. Schieber, M.; Chandel, N.S. ROS function in redox signaling and oxidative stress. *Curr. Biol.* **2014**, *24*, R453–R462.
2. Sies, H. Oxidative stress: A concept in redox biology and medicine. *Redox Biol.* **2015**, *4*, 180–183.
3. Davies, K.J. Protein damage and degradation by oxygen radicals. I. general aspects. *J. Biol. Chem.* **1987**, *262*, 9895–9901.
4. Terman, A.; Brunk U.T. Oxidative Stress, Accumulation of Biological ‘Garbage’, and Aging. *Antioxid. Redox Signal.* **2006**, *8*, 197–204.
5. Dalle-Donne, I.; Aldini, G.; Carini, M.; Colombo, R.; Rossi, R.; Milzani, A.J. The effect of mesedin on the content of oxidative stress biomarkers in the brain tissue in ischemia. *Cell Mol. Med.* **2006**, *10*, 389–406.
6. Finkel T.; Holbrook N. Oxidants, oxidative stress and the biology of ageing. *Nature* **2000**, *408*, 239–247.
7. Sies H. Oxidative stress: Introductory remarks. In *Oxidative Stress*; Sies, H., Ed.; Academic Press: London, UK, 1985; pp. 1–8.
8. Obieziurska M.; Pacuła A.J.; Juhas U.; Antosiewicz J.; Ścianowski J. The Influence of O/S exchange on the Biocatalytical activity of benzisoselenazol-3(2H)-ones. *Catalysts* **2018**, *8*, 493–507.
9. Pacuła, A.J.; Ścianowski, J.; Aleksandrak, K.B. Highly efficient synthesis and antioxidant capacity of *N*-substituted benzisoselenazol-3(2H)-ones. *RSC Adv.* **2014**, *4*, 48959–48962.
10. Scheibye, S.; Kristensen, J.; Lawesson, S.O. Studies on organophosphorus compounds—XXVIII: Synthesis of thiono-, thio- and dithiolactones. *Tetrahedron* **1979**, *35*, 1339–1343.
11. Obieziurska, M.; Pacuła, A.J.; Długosz-Pokorska, A.; Krzemiński, M.; Janecka, A.; Ścianowski, J. Bioselectivity induced by chirality of new terpenyl organoselenium compounds. *Materials* **2019**, *12*, 3579–3591.
12. Obieziurska, M.; Pacuła, A.J.; Laskowska, A.; Długosz-Pokorska, A.; Janecka, A.; Ścianowski, J. Seleninic acid potassium salts as water-soluble biocatalysts with enhanced bioavailability. *Materials* **2020**, *3*, 661.
13. Polêto, M.D.; Rusu, V.H.; Grisci, B.I.; Dorn, M.; Lins, R.D.; Verli, H. Aromatic rings commonly used in medicinal chemistry: Force fields comparison and interactions with water toward the design of new chemical entities. *Front. Pharmacol.* **2018**, *9*, 395–414.
14. Ward, S.E.; Beswick, P. What does the aromatic ring number mean for drug design? *Expert Opin. Drug Discov.* **2014**, *9*, 9–18.
15. Obieziurska-Fabisiak, M.; Pacuła, A.J.; Capoccia, L.; Drogosz-Stachowicz, J.; Janecka, A.; Santi, C.; Ścianowski, J. Phenylselenanyl group incorporation for “glutathione peroxidase-ILike” activity modulation. *Molecules* **2020**, *25*, 3354.
16. Kumakura, F.; Mishra, B.; Priyadarsini, K.I.; Iwaoka, M. A water-soluble cyclic selenide with enhanced glutathione peroxidase-like catalytic activities. *J. Org. Chem.* **2010**, *3*, 440–444.
17. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *J. Immunol. Methods* **1983**, *65*, 55–63.

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).